EctoPharma
  • Home
  • ABOUT US
    • The Company – What we do
    • Business Model
    • Current Work
    • Who’s Who
    • In the Media
      • December 2010
      • September 2010
      • June 2010
      • December 2009
  • OUR PRODUCTS
    • KindaPed™
      • UK Launch of “Hedrin Treat & Go”
      • Properties of KindaPed™
      • Current Lice Treatments
      • Efficacy
      • Market Size
    • Ryboquin™
      • The Background
      • The Process
      • Why Pancreatic Cancer?
  • SHAREHOLDERS
    • Presentations
    • Letters
  • Contact us

Current lice treatments – limitations compared to KindaPed™

  • Not as effective:  lice have become resistant to insecticides in pyrethroid- and malathion- based products
  • Do not kill both lice and eggs
  • Do  not prevent development of resistance to the product
  • High alcohol formulations
  • Smell and/or appearance reveals usage

 

 

Comments are closed.



KindaPed™

  • UK Launch of “Hedrin Treat & Go”
  • Properties of KindaPed™
  • Current Lice Treatments
  • Efficacy
  • Market Size
Go To Top »

Copyright Ectopharma 2011